Calatroni M, Moroni G, Conte E, Stella M, Reggiani F, Ponticelli C
Front Immunol. 2024; 15:1410032.
PMID: 38938561
PMC: 11208682.
DOI: 10.3389/fimmu.2024.1410032.
Yamato M, Shirai T, Ishii Y, Sato H, Ishii T, Fujii H
Clin Rheumatol. 2024; 43(3):1023-1035.
PMID: 38334937
DOI: 10.1007/s10067-024-06904-9.
Radanova M, Vasilev V, Mihaylova G, Kosturkova M, Kishore U, Roumenina L
Int J Mol Sci. 2022; 23(16).
PMID: 36012546
PMC: 9409282.
DOI: 10.3390/ijms23169281.
Rabatscher P, Trendelenburg M
Clin Transl Immunology. 2022; 11(8):e1408.
PMID: 35928801
PMC: 9345742.
DOI: 10.1002/cti2.1408.
Son M
Exp Mol Med. 2022; 54(5):567-572.
PMID: 35562585
PMC: 9098383.
DOI: 10.1038/s12276-022-00774-4.
Intertwined pathways of complement activation command the pathogenesis of lupus nephritis.
Satyam A, Hisada R, Bhargava R, Tsokos M, Tsokos G
Transl Res. 2022; 245:18-29.
PMID: 35296451
PMC: 9167748.
DOI: 10.1016/j.trsl.2022.03.005.
Ocular manifestations and full house membranous nephropathy as a rare presentation of secondary syphilis.
Sockman E, Guffey J, Yednock J, Fisher M
IDCases. 2022; 28:e01461.
PMID: 35284233
PMC: 8908063.
DOI: 10.1016/j.idcr.2022.e01461.
Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies.
Irure-Ventura J, Lopez-Hoyos M
J Transl Autoimmun. 2022; 5:100143.
PMID: 35072035
PMC: 8761754.
DOI: 10.1016/j.jtauto.2022.100143.
Autoantibodies against complement component C1q in systemic lupus erythematosus.
Trendelenburg M
Clin Transl Immunology. 2021; 10(4):e1279.
PMID: 33968409
PMC: 8082710.
DOI: 10.1002/cti2.1279.
Anti-C1q Autoantibodies: Standard Quantification and Innovative ELISA.
Csorba K, Schirmbeck L, Dubler D, Trendelenburg M
Methods Mol Biol. 2021; 2227:107-114.
PMID: 33847935
DOI: 10.1007/978-1-0716-1016-9_10.
Expanding the Role of Complement Therapies: The Case for Lupus Nephritis.
Li N, Birmingham D, Rovin B
J Clin Med. 2021; 10(4).
PMID: 33562189
PMC: 7915321.
DOI: 10.3390/jcm10040626.
SLE: Novel Postulates for Therapeutic Options.
Hosszu K, Valentino A, Peerschke E, Ghebrehiwet B
Front Immunol. 2020; 11:583853.
PMID: 33117397
PMC: 7575694.
DOI: 10.3389/fimmu.2020.583853.
The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy.
Chighizola C, Lonati P, Trespidi L, Meroni P, Tedesco F
Front Immunol. 2020; 11:2084.
PMID: 32973817
PMC: 7481445.
DOI: 10.3389/fimmu.2020.02084.
Pathophysiology and therapy of systemic vasculitides.
Ralli M, Campo F, Angeletti D, Minni A, Artico M, Greco A
EXCLI J. 2020; 19:817-854.
PMID: 32665772
PMC: 7355154.
DOI: 10.17179/excli2020-1512.
C1q A08 Is a Half-Cryptic Epitope of Anti-C1q A08 Antibodies in Lupus Nephritis and Important for the Activation of Complement Classical Pathway.
Wu W, Tan Y, Liu X, Yu F, Zhao M
Front Immunol. 2020; 11:848.
PMID: 32536911
PMC: 7267003.
DOI: 10.3389/fimmu.2020.00848.
Programmed Cell Death Pathways in the Pathogenesis of Systemic Lupus Erythematosus.
Yang F, He Y, Zhai Z, Sun E
J Immunol Res. 2019; 2019:3638562.
PMID: 31871956
PMC: 6913273.
DOI: 10.1155/2019/3638562.
Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?.
Didier K, Bolko L, Giusti D, Toquet S, Robbins A, Antonicelli F
Front Immunol. 2018; 9:541.
PMID: 29632529
PMC: 5879136.
DOI: 10.3389/fimmu.2018.00541.
Clinical utility of anti-C1q antibody in primary and secondary vasculitic conditions.
Jayakanthan K, Gupta A, Mathew J, Ravindran R, Mahasampth G, Danda D
Int J Health Sci (Qassim). 2017; 11(5):3-6.
PMID: 29114186
PMC: 5669508.
Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis.
Mistry P, Kaplan M
Clin Immunol. 2016; 185:59-73.
PMID: 27519955
PMC: 5299061.
DOI: 10.1016/j.clim.2016.08.010.
Anti-C1q in systemic lupus erythematosus.
Stojan G, Petri M
Lupus. 2016; 25(8):873-7.
PMID: 27252264
PMC: 7523495.
DOI: 10.1177/0961203316645205.